Pediatric superior vena cava syndrome: An evidence-based systematic review of the literature

Pediatr Blood Cancer. 2018 Sep;65(9):e27225. doi: 10.1002/pbc.27225. Epub 2018 May 21.

Abstract

Superior vena cava syndrome (SVCS) results in vascular, respiratory, and neurologic compromise. A systematic search was conducted to determine the prevalence of pediatric SVCS subtypes and identify clinical characteristics/treatment strategies that may influence overall outcomes. Data from 101 case reports/case series (142 patients) were analyzed. Morbidity (30%), mortality (18%), and acute complications (55%) were assessed as outcomes. Thrombosis was present in 36%, with multi-modal anticoagulation showing improved outcome by >50% (P = 0.004). Infant age (P = 0.04), lack of collaterals (P = 0.007), acute complications (P = 0.005), and clinical presentation may have prognostic utility that could influence clinical decisions and surveillance practices in pediatric SVCS.

Keywords: cardiovascular complications; clinical characteristics; outcome prediction; superior vena cava syndrome; thrombosis.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Adolescent
  • Age of Onset
  • Anticoagulants / therapeutic use
  • Catheterization, Central Venous / adverse effects
  • Child
  • Child, Preschool
  • Evidence-Based Medicine
  • Heart Defects, Congenital / complications
  • Hematologic Neoplasms / complications
  • Humans
  • Infant
  • Infant, Newborn
  • Prevalence
  • Prognosis
  • Risk Factors
  • Stents
  • Superior Vena Cava Syndrome* / classification
  • Superior Vena Cava Syndrome* / epidemiology
  • Superior Vena Cava Syndrome* / etiology
  • Superior Vena Cava Syndrome* / therapy
  • Thrombophilia / complications
  • Treatment Outcome
  • Vascular Surgical Procedures

Substances

  • Anticoagulants